Tardive Dyskinesia: A Review

Abstract

French

Objective:

To review recent research findings on tardive dyskinesia (TD) with relevance to clinical practice.

Method:

TD is a syndrome of involuntary movements that can occur in association with chronic neuroleptic use. It is of unknown pathophysiology. It can be irreversible, is cosmetically disfiguring, and can be functionally disabling.

Results:

There is as yet no treatment of demonstrated efficacy for TD. It is an iatrogenic disorder whose incidence is increased by age and total cumulative dose of typical neuroleptics. It has been the source of successful litigation in some jurisdictions but, until very recently, there has been no effective antipsychotic agent without this effect.

Conclusion:

This litigation in some jurisdictions has been a major impetus to the development of novel antipsychotic agents. It is less well known that a similar, possibly identical, movement disorder occurs spontaneously particularly in the elderly and inpatients with schizophrenia, and that TD is often reversible.

References

Kane

J.M.

, Jest

D.V.

editors. American Psychiatric Association Task Force Report on Tardive Dyskinesia. A task force report. Washington DC: American Psychiatric Press Inc.; 1992.

Shriqui

C.L.

, Annable

Tardive dyskinesia. In: Shriqui

C.L.

, Nasrallah

H.A.

, editors. Contemporary issues in the treatment of schizophrenia. Washington DC: American Psychiatric Press Inc.; 1995. pp 585–632.

Youssef

H.A.

, Waddington

J.L.

Primitive (developmental) reflexes and diffuse cerebral dysfunction in schizophrenia and bipolar affective disorder: over-representation in patients with tardive dyskinesia.

Biol Psychiatry 1988; 23: 791–796.

Kucharski

L.T.

, Smith

J.W.

, Dunn

D.D.

Mortality and tardive dyskinesia.

Am J Psychiatry 1979; 136: 1228.

McClelland

H.A.

, Dutta

, Metcalfe

Mortality and facial dyskinesia.

Br J Psychiatry 1986; 148: 310–316.

Metha

, Mallya

, Volavka

Mortality of patients with tardive dyskinesia.

Am J Psychiatry 1978; 135: 371–372.

Yassa

, Mohelsky

, Dimitry

Mortality rate in tardive dyskinesia.

Am J Psychiatry 1984; 141: 1018–1019.

Barnes

T.R.

, Kidger

, Gore

S.M.

Tardive dyskinesia: a 3-year follow-up study.

Psychol Med 1983; 13: 71–81.

Casey

D.E.

Tardive dyskinesia: reversible and irreversible. In: Casey

D.E.

, Chase

T.N.

, Christensen

A.V.

Dyskinesia, research and treatment. Berlin: Springer-Verlag; 1985: 88–97.

10.

Gardos

, Cole

J.O.

Problems in the assessment of tardive dyskinesia. In: Fann

W.E.

, Smith

R.C.

, Davis

J.M.

Dyskinesia, research and treatment. New York: Spectrum; 1980. pp 201–214.

11.

Schooler

N.R.

, Kane

J.M.

Research diagnoses for tardive dyskinesia.

Arch Gen Psychiatry 1982; 39: 486–487.

12.

Guy

ECDEU assessment manual for psychopharmacology, revised edition. Washington DC: US Department of Health, Education and Welfare; 1976.

13.

Chouinard

, Ross-Chouinard

, Annable

Extrapyramidal symptom rating scale.

Can J Neurol Sci 1980; 7: 233.

14.

Casey

D.E.

Spontaneous and tardive dyskinesias: clinical and laboratory studies.

J Clin Psychiatry 1985; 46: 42–47.

15.

Kraepelin

E.P.

Dementia praecox and paraphrenia. Barclay

, translator; Robertson

G.M.

, editor. Edinburgh: E and S Livingstone; 1919.

16.

Owens

D.G.

, Johnstone

E.C.

, Frith

C.D.

Spontaneous involuntary disorders of movement: their prevalence, severity and distribution in chronic schizophrenics with and without treatment with neuroleptics.

Arch Gen Psychiatry 1982; 39: 452–461.

17.

Yarden

P.E.

, Discipio

W.J.

Abnormal movements and prognosis in schizophrenia.

Am J Psychiatry 1971; 128: 317–333.

18.

Woerner

, Kane

J.M.

, Lieberman

The prevalence of tardive dyskinesia.

J Clin Psychopharmacol 1991; 1: 34–42.

19.

Kane

J.M.

, Woerner

, Weinhold

Incidence of tardive dyskinesia: five year data from a prospective study.

Psychopharmacol Bull 1984; 20: 387–389.

20.

Kane

J.M.

, Woerner

, Borenstein

Integrating incidence and prevalence of tardive dyskinesia.

Psychopharmacol Bull 1986; 22: 54–58.

21.

Kane

J.M.

, Honigfeld

, Singer

Clozapine in treatment-resistant schizophrenics.

Psychopharmacol Bull 1988; 24: 62–67.

22.

Glazer

, Morgenstern

Identifying risk factors for tardive dyskinesia: a prospective study [abstract S-98-419].

Neuropsychopharmacol 1994; 10(3 Suppl):440S.

23.

Barron

E.T.

, McCreadie

R.G.

One-year follow-up of tardive dyskinesia.

Br J Psychiatry 1983; 143: 423–424.

24.

Inada

, Yagi

Current status of tardive dyskinesia in Japan [abstract S-98-422].

Neuropsychopharmacol 94;10(3 Suppl): 442S.

25.

Gardos

, Casey

D.E.

, Cole

J.O.

Changes in dyskinesia and parkinsonism over fifteen years [abstract S-98-4232].

Neuropsychopharmacol 1994; 10(3 Suppl):443S.

26.

Kane

J.M.

, Smith

J.M.

Tardive dyskinesia: prevalence and risk factors, 1959–1979.

Arch Gen Psychiatry 1982; 39: 473–481.

27.

Smith

J.M.

, Baldessarini

R.J.

Changes in prevalence, severity and recovery in tardive dyskinesia with age.

Arch Gen Psychiatry 1980; 37: 1368–1373.

28.

Saltz

B.L.

, Woerner

M.G.

, Kane

J.M.

Prospective study of tardive dyskinesia incidence in the elderly.

J Am Med Assoc 1991; 266: 2402–2406.

29.

Smith

J.M.

, Dunn

D.D.

Sex differences in the prevalence of severe tardive dyskinesia.

Am J Psychiatry 1979; 136: 1080–1082.

30.

Ganzini

, Casey

D.E.

, Hoffman

W.F.

Tardive dyskinesia and diabetes mellitus.

Psychopharmacol Bull 1992; 28: 281–286.

31.

Dixon

, Weiden

P.J.

, Haas

Increased tardive dyskinesia in alcohol abusing schizophrenic patients.

Compr Psychiatry 1992; 33: 121–122.

32.

Grimes

J.D.

, Hassan

M.N.

, Preston

D.N.

Adverse neurologic effects of metoclopramide.

Can Med Assoc J 1982; 126: 23–25.

33.

Mahler

J.C.

, Brown

R.P.

More dyskinesia.

N Engl J Med 1987; 316: 412–413.

34.

Baldessarini

R.J.

, chairman. Task Force Report 18 on Tardive Dyskinesia. A task force report of the APA on late neurological effects of antipsychotic drugs. Washington DC: American Psychiatric Association; 1980.

35.

Glazer

W.M.

Doradrenergic function and tardive dyskinesia.

Psychiatric Ann 1989; 19: 297–301.

36.

Crow

T.J.

, Cross

A.J.

, Johnstone

E.C.

Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in D₂ receptors?

J Clin Psychopharmacol 1982; 5: 336–340.

37.

Kornhuber

, Riederer

, Reynolds

G.P.

[³H]spiperone binding sites in postmortem brains from schizophrenia patients: relationship to neuroleptic drug treatment, abnormal movements and positive symptoms.

J Neural Transm 1989; 75: 1–10.

38.

Pall

H.S.

, Williams

A.C.

, Blake

D.R.

Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines.

Lancet 1987; ii:596–599.

39.

Lohr

J.B.

, Underhill

, Moir

Lipid perioxidation in CSF: relationship to catecholamines and tardive dyskinesia.

Biol Psychiatry 1989; 25: 71A.

40.

Chouinard

, Jones

, Remington

A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.

J Clin Psychopharmacol 1993; 13: 25–40.

41.

Thaker

G.K.

, Nguyen

J.A.

, Strauss

M.E.

Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy.

Am J Psychiatry 1990; 147: 445–451.

42.

Shriqui

C.L.

, Annable

Tardive dyskinesia. In: Shriqui

C.L.

, Nasrallah

H.A.

, editors. Contemporary issues in the treatment of schizophrenia. Washington DC: American Psychiatric Press Inc.; 1995. pp 585–632.

43.

Adler

L.A.

Vitamin E treatment of TD: development of a VA Cooperative study [abstract S-98-424].

Neuropsychopharmacol 1994; 10(3 Suppl):444S.

44.

Kennedy

N.J.

, Sanborn

J.S.

Disclosure of tardive dyskinesia: effect of written policy on risk disclosure.

Psychopharmacol Bull 1992; 28: 93–100.